Drug delivery treatment device

• US 9,668,917 B2
• Filed: 07/20/2015
• Issued: 06/06/2017
• Est. Priority Date: 01/17/2006
• Status: Active Grant

• Current Assignee: Alcon Incorporated
• Original Assignee: Novartis Ag
• Inventors: Reich, Cary J., Gifford, III, Hanson S.
• Primary Examiner(s): STIGELL, THEODORE J
• Application Number:
  US14/804,008
• Publication Number:
  US 20150320596A1
• Time in Patent Office: 687 Days
• CPC Class Codes: A61F 9/0008 Introducing ophthalmic products into the ocular cavity or retaining products therein putting in contact lenses A61F9/0061; introducing or retaining media in cavities of the body in general A61M31/00
• CPC Class Codes: A61F 9/0017 implantable in, or in contact with, the eye, e.g. ocular inserts
• CPC Class Codes: A61F 9/00781 Apparatus for modifying intraocular pressure, e.g. for glaucoma treatment drainage implants in general A61M27/002
• CPC Class Codes: A61M 31/00 Devices for introducing or retaining media, e.g. remedies, in cavities of the body A61M25/00 takes precedence ; introducing or retaining ophthalmic products into the ocular cavities A61F9/0008
• CPC Class Codes: A61M 39/22 Valves or arrangement of valves A61M39/02, A61M39/0247, A61M39/16 take precedence; regulating valves in infusion systems A61M5/16881; in devices worn by the patient for the reception of urine, faeces, catamenial or other discharge, or in colostomy devices A61F5/4405

Abstract

Disclosed are devices and methods for treatment of eye disease. The suprachoroidal space is used as a conduit within which to place a drug delivery device. One such drug delivery device may be a tube, wicking element, bioabsorbable polymer structure, or other configuration of drug delivery substrate. The delivery device may include a port on the proximal end to assist in repeat injection, and may include a reservoir to either collect flow from the aqueous to concentrate it along the length of the device, or act as a repository for injected agent.

Claims

1. A method of delivering drug into the eye, comprising:

inserting an elongate member through a cornea and through an anterior chamber of the eye, wherein the elongate member has a first end, a second end, and an internal lumen with a first opening near the first end and a second opening near the second end;

positioning the elongate member in the eye such that the first end is in the anterior chamber, the second end is in communication with a suprachoroidal space of the eye, and at least a portion of the elongate member between the first end and the second end is positioned between the sclera and a ciliary body of the eye;

placing a treatment medium onto an outer surface of the eye; and

causing the treatment medium to flow into the internal lumen of the elongate member and into the suprachoroidal space through the internal lumen of the elongate member.

2. A method as in claim 1, wherein the treatment medium flows into the anterior chamber via tear film.

3. A method as in claim 1, wherein the elongate member is implanted in the eye such that the second end is positioned in an anterior portion of the eye.

4. A method as in claim 1, wherein the elongate member is implanted in the eye such that the second end is positioned between a sclera and a choroid of the eye.

5. A method as in claim 1, wherein the elongate member is implanted in the eye such that the second end is positioned between a sclera and a ciliary body of the eye.

6. A method as in claim 1, wherein placing a treatment medium onto an outer surface of the eye comprises placing a drop of treatment medium onto an outer surface of the eye.

7. A method as in claim 1, wherein the elongate member is implanted in the eye such that the elongate member is positioned adjacent a scleral spur of the eye.

8. A method as in claim 1, wherein the elongate member is implanted in the eye such that no portion of the elongate member between the first end and the second end is positioned inside the sclera.